| Jul 27 |
Eyes On The FOMC, Tech Heavyweight Reports, And OPEC+ Meeting
|
| Jul 25 |
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
|
| Jul 16 |
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
|
| Jun 20 |
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
|
| Jun 18 |
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
|
| May 29 |
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
|
| May 21 |
Alto Neuroscience appoints Michael Hanley as COO
|
| May 21 |
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
|
